Journal of Nuclear Medicine: 62 (10)

October 1, 2021; Volume 62,Issue 10

Cover image

FEATURED ARTICLE

A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors. Wenjia Zhu et al. See page 1398.

In this issue

Issue highlights

A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules

Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
⁶⁸Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸Ga-FAPI PET Prospective Observational Trial

More...

Main menu

User menu

Search

Table of Contents

Cover image

In this issue

Issue highlights

Jump to